• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

About FDA

  • Print
  • Share
  • E-mail

Materials from Webinar on Access to Investigational Drugs

Do you have questions about the use of investigational drugs for treatment purposes?

Expanded access, sometimes called "compassionate use," is the use of an investigational drug outside of a clinical trial to treat a patient with a serious or immediately life-threatening disease or condition who has no comparable or satisfactory alternative treatment options. 

On Tuesday, February 23, at 3 p.m. ET, the FDA hosted a 30-minute webinar on Access to Investigational Drugs. The featured speakers, Theresa Toigo, Director, Office of Special Health Issues and Richard Klein, HIV/AIDS Program Director, Office of Special Health Issues, discussed factors to consider in deciding whether to seek access to an investigational drug and the ways to access investigational drugs.  

Title:  Access to Investigational Drugs
Duration: 00:34:07       
Web address for viewing: https://webmeeting.nih.gov/p14874544/  

Download presentation slides (PDF)

Basics Question toggle Show all related FDA Basics Questions


How helpful was this information?


Not HelpfulArrow pointing to the rightVery Helpful

Please limit your feedback to 1000 characters.

Please limit your feedback to 1000 characters.

If you would like to ask a specific question, please visit our "Contact Us" page for more information about how to contact FDA.

Please note that any information you submit may become public or subject to release under the Freedom of Information Act (FOIA). For more information, read about our privacy policies and the FOIA.